1. Home
  2. EVR vs MDGL Comparison

EVR vs MDGL Comparison

Compare EVR & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evercore Inc.

EVR

Evercore Inc.

HOLD

Current Price

$341.78

Market Cap

13.4B

Sector

Finance

ML Signal

HOLD

Logo Madrigal Pharmaceuticals Inc.

MDGL

Madrigal Pharmaceuticals Inc.

HOLD

Current Price

$515.02

Market Cap

12.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVR
MDGL
Founded
1995
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.4B
12.1B
IPO Year
2006
2005

Fundamental Metrics

Financial Performance
Metric
EVR
MDGL
Price
$341.78
$515.02
Analyst Decision
Buy
Strong Buy
Analyst Count
8
12
Target Price
$359.38
$674.45
AVG Volume (30 Days)
481.7K
349.5K
Earning Date
04-29-2026
05-06-2026
Dividend Yield
0.97%
N/A
EPS Growth
54.74
41.32
EPS
14.05
N/A
Revenue
$3,880,084,000.00
$180,133,000.00
Revenue This Year
$22.69
$58.39
Revenue Next Year
$13.31
$48.55
P/E Ratio
$24.50
N/A
Revenue Growth
29.49
N/A
52 Week Low
$192.77
$265.00
52 Week High
$388.71
$615.00

Technical Indicators

Market Signals
Indicator
EVR
MDGL
Relative Strength Index (RSI) 58.89 53.07
Support Level $334.70 $503.93
Resistance Level $370.61 $539.17
Average True Range (ATR) 11.73 17.01
MACD 0.68 -2.96
Stochastic Oscillator 59.88 34.66

Price Performance

Historical Comparison
EVR
MDGL

About EVR Evercore Inc.

Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. Evercore operates globally, with a particularly strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Share on Social Networks: